Abstract
Background Non-pharmaceutical interventions have been implemented to reduce transmission of SARS-CoV-2 in the UK. Projecting the size of an unmitigated epidemic and the potential effect of different control measures has been critical to support evidence-based policymaking during the early stages of the epidemic.
Methods We used a stochastic age-structured transmission model to explore a range of intervention scenarios, including the introduction of school closures, social distancing, shielding of elderly groups, self-isolation of symptomatic cases, and extreme “lockdown”-type restrictions. We simulated different durations of interventions and triggers for introduction, as well as combinations of interventions. For each scenario, we projected estimated new cases over time, patients requiring inpatient and critical care (intensive care unit, ICU) treatment, and deaths.
Findings We found that mitigation measures aimed at reducing transmission would likely have decreased the reproduction number, but not sufficiently to prevent ICU demand from exceeding NHS availability. To keep ICU bed demand below capacity in the model, more extreme restrictions were necessary. In a scenario where “lockdown”-type interventions were put in place to reduce transmission, these interventions would need to be in place for a large proportion of the coming year in order to prevent healthcare demand exceeding availability.
Interpretation The characteristics of SARS-CoV-2 mean that extreme measures are likely required to bring the epidemic under control and to prevent very large numbers of deaths and an excess of demand on hospital beds, especially those in ICUs.
Evidence before this study As countries have moved from early containment efforts to planning for the introduction of large-scale non-pharmaceutical interventions to control COVID-19 outbreaks, epidemic modelling studies have explored the potential for extensive social distancing measures to curb transmission. However, it remains unclear how different combinations of interventions, timings, and triggers for the introduction and lifting of control measures may affect the impact of the epidemic on health services, and what the range of uncertainty associated with these estimates would be.
Added value of this study Using a stochastic, age-structured epidemic model, we explored how eight different intervention scenarios could influence the number of new cases and deaths, as well as intensive care beds required over the projected course of the epidemic. We also assessed the potential impact of local versus national targeting of interventions, reduction in leisure events, impact of increased childcare by grandparents, and timing of triggers for different control measures. We simulated multiple realisations for each scenario to reflect uncertainty in possible epidemic trajectories.
Implications of all the available evidence Our results support early modelling findings, and subsequent empirical observations, that in the absence of control measures, a COVID-19 epidemic could quickly overwhelm a healthcare system. We found that even a combination of moderate interventions – such as school closures, shielding of older groups and self-isolation – would be unlikely to prevent an epidemic that would far exceed available ICU capacity in the UK. Intermittent periods of more intensive lockdown-type measures are predicted to be effective for preventing the healthcare system from being overwhelmed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NGD was funded by the National Institute for Health Research Health Protection Research Unit in Immunisation (NIHR; HPRU-2012-10096). AJK was funded by the Wellcome Trust (WT; 206250/Z/17/Z). RME was funded by Health Data Research UK (MR/S003975/1). AG was funded by the Global Challenges Research Fund (GCRF; ES/P010873/1). WJE was funded by the European Union's Horizon 2020 research and innovation programme - project EpiPose (No 101003688). We acknowledge the London School of Hygiene & Tropical Medicine COVID-19 modelling group, who contributed to this work. Their funding sources are as follows: TJ: Research Council UK / Economic and Social Research Council ES/P010873/1; UK Public Health Rapid Support Team; NIHR HPRU in Modelling Methodology. KO'R: Bill and Melinda Gates Foundation (BMGF) OPP1191821. AE: The Nakajima Foundation; The Alan Turing Institute. JH: Wellcome Trust (WT) 210758/Z/18/Z. ESN: BMGF OPP1183986. BJQ: NIHR 16/137/109 using UK Aid funding. CIJ: GCRF project ‘RECAP’ managed through RCUK and ESRC ES/P010873/1. TWR: WT 206250/Z/17/Z. PK: BMGF INV-003174. NIB: WT 210758/Z/18/Z. S Funk: WT 210758/Z/18/Z. SA: WT 210758/Z/18/Z. HG: Department of Health and Social Care ITCRZ 03010 using UK Aid funding, managed by the NIHR. CABP: BMGF OPP1184344. S Flasche: WT 208812/Z/17/Z. MJ: BMGF INV-003174, NIHR 16/137/109. SC: WT 208812/Z/17/Z. KP: BMGF INV-003174. CD: NIHR 16/137/109. JCE: European Research Council (ERC) Starting Grant, Action Number #757699. SRP: BMGF OPP1180644. KvZ: Elrha’s Research for Health in Humanitarian Crises Programme, funded by the UK Government (DFID), WT, and NIHR. FS: NIHR EPIC grant (16/137/109). JDM: WT 210758/Z/18/Z. AR: NIHR PR-OD-1017-20002. MA: BMGF OPP1191821. GK: UK Medical Research Council MR/P014658/1. RMGJH: ERC Starting Grant, Action Number #757699. YL: BMGF INV-003174, NIHR 16/137/109. The views expressed in this publication are those of the authors and not necessarily those of any of their funders.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All analysis code and data are available at https://github.com/cmmid/covid-uk.
